Sugi Predict

Sugi Predict / Compounds / SCHEMBL2280918

SCHEMBL2280918

SCHEMBL2280918

Brc1ccc(Nc2ccccc2)nc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.60
▸ HCAR3 P49019 1/20 0.56
▸ MEN1 O00255 4/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ MAPT P10636 3/20 0.53
▸ LMNA P02545 3/20 0.53
▸ PDGFRB P09619 1/20 0.47
▸ PDGFRA P16234 1/20 0.47
▸ RAB9A P51151 5/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ ALPG P10696 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ PKM P14618 1/20 0.46
▸ GRM5 P41594 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31532396 1.00 ALDH1A1 (0.60) ALDH1A1HCAR3MEN1KMT2AMAPT
SCHEMBL28403065 0.88 RAB9A (0.47) ALDH1A1HCAR3MEN1KMT2AMAPT
SCHEMBL29501850 0.88 RAB9A (0.47) ALDH1A1HCAR3MEN1KMT2AMAPT
SCHEMBL355054 0.83 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AMAPTLMNA
SCHEMBL20172471 0.82 NPC1 (0.47) ALDH1A1MEN1KMT2ARAB9AKDM4E
SCHEMBL4516270 0.81 NPC1 (0.62) ALDH1A1MEN1KMT2AMAPTLMNA
SCHEMBL3245214 0.81 HAO1 (0.47) ALDH1A1MEN1KMT2AMAPTRAB9A
SCHEMBL29849858 0.81 NPC1 (0.62) ALDH1A1MEN1KMT2AMAPTLMNA
SCHEMBL3872115 0.81 MEN1 (0.55) ALDH1A1MEN1KMT2AMAPTLMNA
SCHEMBL181114 0.79 MEN1 (0.52) ALDH1A1MEN1KMT2AMAPTPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250257035-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2025-08-14 — — US disclosed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US disclosed
US-12098130-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2024-09-24 — — US disclosed
US-11981661-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2024-05-14 — — US disclosed
US-20230391723-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2023-12-07 — — US disclosed
US-11702388-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2023-07-18 — — US disclosed
EP-4208456-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2023-07-12 — — EP disclosed
CN-115989228-A Heterocyclic compounds 豪夫迈·罗氏有限公司 2023-04-18 — — CN disclosed
US-20220098176-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2022-03-31 — — US disclosed
US-20210230116-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2021-07-29 — — US disclosed
US-7524843-B2 N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide as an enzyme inhibitor for both Fab I and Fab K which are used in the biosynthesis of fatty acids; enoyl-acyl-carrier protein renamed Fab 1; bactericides; fungicides; Staphylococcus aureus; antibiotics AFFINIUM PHARMACEUTICALS, INC. (CA) 2009-04-28 — — US disclosed
US-20080125423-A1 Fab I Inhibitors DEBIOPHARM INTERNATIONAL SA (CH) 2008-05-29 — — US disclosed
US-20050250810-A1 FAB I inhibitors AFFINIUM PHARMACEUTICALS, INC. (CA) 2005-11-10 — — US disclosed
CN-1197860-C FAB I inhibitors SMITHKLINE BEECHAM CORP (CA) 2005-04-20 — — CN disclosed
US-6846819-B1 Fab I inhibitors AFFINIUM PHARMACEUTICALS, INC. (CA) 2005-01-25 — — US disclosed
EP-1226138-B1 FAB I INHIBITORS AFFINIUM PHARM INC (CA) 2004-12-29 — — EP disclosed
EP-1226138-A4 FAB I INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 — — EP disclosed
CN-1378542-A Antigen binding fragment I inhibitors SMITHKLINE BEECHAM CORP (US) 2002-11-06 — — CN disclosed
EP-1226138-A1 FAB I INHIBITORS SmithKline Beecham Corporation (US) 2002-07-31 — — EP disclosed
WO-2001027103-A1 FAB I INHIBITORS SMITHKLINE BEECHAM CORPORATION (GB) 2001-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257035-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A ALDH1A1 110/4885HCAR3 772/4885MEN1 3857/4885
US-20220098176-A1 HETEROCYCLIC COMPOUNDS CBR3, BRIX1, CCNY ALDH1A1 1218/4885HCAR3 416/4885MEN1 1044/4885
US-20050250810-A1 FAB I inhibitors SERPINB1, TFPI, TFPI2 ALDH1A1 2491/4885HCAR3 3528/4885MEN1 3468/4885
US-20230391723-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A ALDH1A1 110/4885HCAR3 772/4885MEN1 3857/4885
US-20210230116-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A ALDH1A1 110/4885HCAR3 772/4885MEN1 3857/4885
US-20080125423-A1 Fab I Inhibitors SERPINB1, TFPI, TFPI2 ALDH1A1 2491/4885HCAR3 3528/4885MEN1 3468/4885
US-11981661-B2 Heterocyclic compounds CBR3, BRIX1, CCNY ALDH1A1 1218/4885HCAR3 416/4885MEN1 1044/4885
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 ALDH1A1 411/4885HCAR3 144/4885MEN1 2422/4885
US-11702388-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A ALDH1A1 110/4885HCAR3 772/4885MEN1 3857/4885
US-12098130-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A ALDH1A1 110/4885HCAR3 772/4885MEN1 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.